Stock AVIR ATEA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
3.96 USD +3.39% Intraday chart for Atea Pharmaceuticals, Inc. +6.74% +29.84%
27/03 Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients CI
28/02 Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Atea Pharmaceuticals Reports 'Positive' Results on Hepatitis C Virus, COVID Trials; Shares Jump After Hours
Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19
Atea Pharmaceuticals Says Bemnifosbuvir, Ruzasvir Combination Results Show Promise to Treat Hepatitis C Virus
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Atea Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceuticals, Inc..
Atea Pharmaceuticals Receives Cash Takeover Proposal From Tang Capital Affiliate Concentra Biosciences; Shares Jump
Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Atea Pharmaceuticals, Inc. Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
Atea Pharmaceuticals, Inc. Showcases New Data Favorable Profile of Bemnifosbuvir for Treatment of Covid-19 and Hepatitis C Presented At 2023 International Conference on Antiviral Research
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies At CROI 2023
Atea Pharmaceuticals, Inc. Provides an Update on the Clinical Development Programs for 2023
Atea Pharmaceuticals Says It Dosed First Patient in Phase 3 Trial of Bemnifosbuvir to Treat COVID-19
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AVIR Stock
  4. News Atea Pharmaceuticals, Inc.
  5. Other languages